96 related articles for article (PubMed ID: 3581097)
1. Pharmacokinetics of high-dose teniposide.
Holthuis JJ; de Vries LG; Postmus PE; van Oort WW; Verleun H; Hulshoff A; Sleijfer DT; Mulder NH
Cancer Treat Rep; 1987 Jun; 71(6):599-603. PubMed ID: 3581097
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of teniposide in patients with ovarian cancer.
D'Incalci M; Rossi C; Sessa C; Urso R; Zucchetti M; Farina P; Mangioni C
Cancer Treat Rep; 1985 Jan; 69(1):73-7. PubMed ID: 3967261
[TBL] [Abstract][Full Text] [Related]
3. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.
Canal P; Bugat R; Michel C; Roche H; Soula G; Combes PF
Cancer Chemother Pharmacol; 1985; 15(2):149-52. PubMed ID: 4017164
[TBL] [Abstract][Full Text] [Related]
5. Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.
Lee T; Roberts D
Cancer Res; 1984 Jul; 44(7):2986-90. PubMed ID: 6722822
[TBL] [Abstract][Full Text] [Related]
6. Teniposide (VM26) disposition in children with leukemia.
Sinkule JA; Stewart CF; Crom WR; Melton ET; Dahl GV; Evans WE
Cancer Res; 1984 Mar; 44(3):1235-7. PubMed ID: 6581866
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
[TBL] [Abstract][Full Text] [Related]
8. Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice.
Broggini M; Colombo T; D'Incalci M
Cancer Treat Rep; 1983 Jun; 67(6):555-9. PubMed ID: 6861161
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
Hande KR; Wedlund PJ; Noone RM; Wilkinson GR; Greco FA; Wolff SN
Cancer Res; 1984 Jan; 44(1):379-82. PubMed ID: 6690051
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient.
Holthuis JJ; Van de Vyver FL; van Oort WJ; Verleun H; Bakaert AB; De Broe ME
Cancer Treat Rep; 1985 Nov; 69(11):1279-82. PubMed ID: 3004725
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
[TBL] [Abstract][Full Text] [Related]
12. Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas.
O'Connell MJ; Anderson J; Merrill JM; Bennett JM; Glick JH; Berard CW; Neiman RS; Brodovsky HS
Cancer Treat Rep; 1982 Dec; 66(12):2021-5. PubMed ID: 6814757
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of etoposide in gestochoriocarcinoma.
D'Incalci M; Sessa C; Rossi C; Roviaro G; Mangioni C
Cancer Treat Rep; 1985 Jan; 69(1):69-72. PubMed ID: 2981622
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.
Evans WE; Sinkule JA; Crom WR; Dow L; Look AT; Rivera G
Cancer Chemother Pharmacol; 1982; 7(2-3):147-50. PubMed ID: 7083455
[TBL] [Abstract][Full Text] [Related]
15. Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.
Stewart DJ; Richard MT; Hugenholtz H; Dennery J; Nundy D; Prior J; Montpetit V; Hopkins HS
J Neurooncol; 1984; 2(4):315-24. PubMed ID: 6530619
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of mitomycin C in humans.
den Hartigh J; McVie JG; van Oort WJ; Pinedo HM
Cancer Res; 1983 Oct; 43(10):5017-21. PubMed ID: 6411336
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?
Allen LM; Tejada F; Okonmah AD; Nordqvist S
Cancer Chemother Pharmacol; 1982; 7(2-3):151-6. PubMed ID: 7083456
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26).
Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1982 May; 66(5):1121-5. PubMed ID: 7044533
[TBL] [Abstract][Full Text] [Related]
19. Transsynovial kinetics of lonazolac and its hydroxy metabolite in synovitis patients.
Deneke J; Luckow V; Guserle R; Pässler HH
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):418-24. PubMed ID: 9726694
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
